Is Ketamine-Assisted Therapy Evidence-Based?
Yes, ketamine-assisted therapy is evidence-based, but the full answer deserves nuance.
Ketamine has a strong and growing body of research for rapid symptom reduction, especially in treatment-resistant depression. Esketamine, a ketamine-related nasal spray, is FDA-approved for certain forms of treatment-resistant depression and must be administered in certified medical settings with monitoring because of risks such as sedation, dissociation, and misuse. Racemic ketamine itself is FDA-approved as an anesthetic, but it is not FDA-approved for psychiatric disorders, which means its use for depression, anxiety, PTSD, or trauma-related symptoms is considered off-label. The FDA has also warned about compounded ketamine products, especially when used without adequate medical monitoring.
Ketamine-assisted therapy, often called KAP, sits in a slightly different category. It combines ketamine medicine sessions with psychotherapy, preparation, and integration. The evidence base for KAP is not yet as large or standardized as the research on IV ketamine or FDA-approved intranasal esketamine. However, research is increasingly showing that when ketamine is paired with skilled therapeutic support, it may help people not only reduce symptoms, but also work with the emotional, relational, and nervous-system patterns underneath those symptoms. A 2024 retrospective study of ketamine-assisted psychotherapy found sustained reductions in depression, anxiety, and PTSD symptoms at three and six months, though the authors also noted high attrition and called for more prospective research.
At Solthera Therapy, this distinction matters. Ketamine-assisted therapy is not simply about “taking ketamine.” It is about creating a carefully supported therapeutic process where the medicine may open a window for insight, emotional processing, somatic awareness, and new patterns of self-relationship.
What Does “Evidence-Based” Mean in Ketamine-Assisted Therapy?
When people ask whether ketamine-assisted therapy is evidence-based, they are often asking several different questions at once:
Is ketamine itself supported by research?
Is therapy during or around ketamine supported by research?
Does KAP help with more than short-term symptom relief?
Is it safe?
Is it appropriate for trauma, attachment wounds, identity work, or relational patterns?
The answer varies depending on the question.
Ketamine as a biological treatment has substantial research behind it, particularly for rapid antidepressant effects. IV ketamine and intranasal esketamine have been studied more extensively than psychotherapy-inclusive KAP models. Esketamine has gone through the FDA approval pathway for specific depression indications, while off-label ketamine treatment has not been approved by the FDA for psychiatric use.
KAP has a smaller but growing research base. A systematic review published in 2026 examined ketamine-assisted psychotherapy for treatment-resistant depression, reflecting the increasing academic attention being given to KAP as a distinct treatment model rather than simply medication administration plus optional support.
That is important because “evidence-based” does not always mean “the evidence is complete.” It means a treatment is grounded in research, clinical theory, observed outcomes, and responsible practice. In the case of KAP, the research is promising, but still developing. Ethical providers should be honest about both sides: ketamine-assisted therapy is supported by emerging evidence, and we still need more large, randomized, long-term studies to better understand who benefits most, what protocols work best, and how to optimize safety and durability.
KAP Is Different From IV Ketamine or Intranasal Esketamine
One of the most important distinctions is the difference between ketamine treatment for symptom reduction and ketamine-assisted therapy for therapeutic change.
In many IV ketamine or intranasal esketamine models, the primary goal is symptom reduction. A person may receive the medication in a medical setting, be monitored during and after dosing, and track changes in symptoms such as depression, suicidal ideation, or anxiety. This can be meaningful and even life-changing for some people.
Ketamine-assisted therapy includes symptom relief as a goal, but it also asks a deeper therapeutic question:
What becomes possible when the nervous system has more flexibility, the inner critic softens, defenses loosen, or a person can access painful material without being overwhelmed?
In KAP, the medicine session is not viewed as the whole treatment. It is part of a larger arc that may include:
Preparation before medicine sessions
Therapeutic intention-setting
Somatic and nervous-system resourcing
Attachment-aware support
The medicine experience itself
Integration afterward
Behavioral and relational change between sessions
This is where KAP may offer something different from medication-only models. The medicine may create a state in which familiar mental loops become less rigid. Therapy helps the client make meaning of what arises and translate insight into lived change.
Why Preparation Matters
Preparation is not a formality. It is part of the treatment.
Before a ketamine session, a therapist may help the client clarify intentions, identify emotional themes, build grounding skills, and understand what may happen during the experience. This can be especially important for people with complex trauma, attachment wounds, dissociation, relational anxiety, or histories of feeling unsafe in altered states.
Preparation can also help clients shift from a passive mindset — “I hope the medicine fixes me” — into a collaborative therapeutic stance: “I am entering this experience with support, curiosity, and tools.”
At Solthera Therapy, preparation may include somatic mindfulness, nervous-system regulation, parts work, attachment awareness, and trauma-informed education. The goal is not to control the experience. The goal is to help the client feel sufficiently supported to meet what arises.
That distinction is clinically important. Ketamine can bring forward emotion, imagery, memories, bodily sensations, spiritual themes, grief, fear, or unexpected insight. Without preparation, a person may feel confused by the experience or struggle to use it therapeutically. With preparation, even challenging material may become workable.
Why Integration Is Central to the Evidence-Informed KAP Model
Integration is where ketamine-assisted therapy often becomes more than a temporary experience.
A medicine session may reveal something powerful: a new perspective on depression, a moment of compassion toward a younger self, a felt sense of safety, a release of grief, or a recognition of how old survival strategies are still shaping relationships. But insight alone does not always change a life.
Integration asks: what do we do with what happened?
This may include exploring the meaning of images or memories, tracking emotional shifts, practicing new boundaries, updating self-talk, strengthening coping skills, or noticing how the nervous system responds differently after the session.
This is also where KAP may support longer-lasting change. The founder’s clinical perspective captures this well: IV ketamine and intranasal ketamine are often oriented primarily toward symptom reduction, while KAP is also oriented toward therapeutic change — helping people shift thought patterns, behaviors, identity, self-image, self-talk, and relational patterns.
That is the heart of the KAP model. The medicine may open a window. Therapy helps the person walk through it.
What Conditions Has KAP Been Studied For?
The strongest ketamine research overall has focused on depression, particularly treatment-resistant depression. KAP research is broader but less mature. Studies have examined or begun to examine KAP for depression, anxiety, PTSD, substance use disorders, chronic pain, and related mental health concerns.
The 2024 retrospective effectiveness study of KAP found improvements in self-reported depression, anxiety, and PTSD symptoms at one, three, and six months after treatment. The study included adults who had not responded adequately to prior interventions and received KAP across multiple clinics. The findings were promising, but the high loss to follow-up means the results should be interpreted carefully.
Research has also begun examining ketamine-assisted psychotherapy for substance use. A 2026 Nature Mental Health study evaluated ketamine-assisted Mindfulness-Oriented Recovery Enhancement for opioid use disorder, reflecting interest in combining ketamine with structured psychotherapy approaches rather than studying the drug effect alone.
This matters because many clients do not come to therapy with one isolated symptom. They may come with depression intertwined with trauma, shame, relational pain, grief, hormonal mental health concerns, attachment wounds, or a long-standing sense of being disconnected from themselves. KAP research is still catching up to the complexity of real clinical life.
How Ketamine May Support Therapeutic Change
Ketamine is often described as a dissociative anesthetic, but in therapeutic contexts, people may experience a wide range of states: distance from habitual thinking, softened defenses, increased emotional access, symbolic imagery, a sense of spaciousness, or a temporary loosening of rigid self-beliefs.
From a psychotherapy perspective, these shifts may be useful because many people are not simply suffering from “negative thoughts.” They are often living inside deeply learned patterns:
“I am too much.”
“I am not safe.”
“I have to take care of everyone.”
“I cannot trust my feelings.”
“My needs will push people away.”
“I am broken.”
Ketamine may temporarily change the relationship to those beliefs. A client may be able to observe a pattern rather than be fused with it. They may feel compassion where they usually feel shame. They may access grief without collapsing. They may sense the body differently. They may see a relationship pattern with more clarity.
Therapy helps turn that opening into practice. This might include Internal Family Systems-informed parts work, EMDR-informed trauma processing, somatic awareness, mindfulness, attachment repair, relational work, or behavioral change. At Solthera Therapy, KAP is understood through an integrative, trauma-informed lens that includes somatic mindfulness, nervous-system regulation, attachment healing, IFS-informed work, EMDR training, Brainspotting, Hakomi, Sensorimotor Psychotherapy, Somatic Experiencing, DBT/CBT, Gestalt, Emotionally Focused Therapy, Relational Life Therapy, and harm-reduction principles.
The medicine is not treated as magic. It is treated as a catalyst within a therapeutic container.
Evidence-Based Does Not Mean Risk-Free
A trustworthy answer must include safety.
Ketamine can produce sedation, dissociation, changes in blood pressure and heart rate, nausea, anxiety, disorientation, and other psychological or physical effects. The FDA has specifically warned that compounded ketamine products used without appropriate monitoring can pose risks, including sedation, dissociation, psychiatric events, blood pressure increases, respiratory depression, bladder symptoms, misuse, and abuse.
This does not mean ketamine can never be used appropriately in mental health care. It means it should be approached with medical screening, appropriate prescribing, monitoring, informed consent, and a clear therapeutic plan.
For many people, KAP is not appropriate as a casual or at-home experiment. It is also not a substitute for crisis care, ongoing psychiatric support when needed, or medical treatment. A strong KAP model includes collaboration, screening for contraindications, attention to medications and medical history, and careful consideration of trauma history, dissociation, substance use risk, and current stability.
What Makes KAP Clinically Different at Solthera Therapy
Solthera Therapy approaches ketamine-assisted therapy as part of a broader healing process, not a stand-alone intervention.
For clients in Marin County, San Rafael, Berkeley, the East Bay, throughout California via telehealth where appropriate, and Washington State, the therapeutic focus is not only “Can symptoms decrease?” but also:
Can you relate to yourself with more compassion?
Can your nervous system learn more flexibility?
Can old attachment wounds be met without shame?
Can trauma memories become less defining?
Can relational patterns become more conscious?
Can you build coping skills that last beyond the medicine session?
Can insight become embodied change?
This is especially relevant for clients navigating complex trauma, cPTSD, relational anxiety, grief, identity exploration, PMDD or hormonal mental health concerns, spiritual emergence, midlife transitions, LGBTQIA+ concerns, BIPOC identity stressors, poly/kink-affirming therapy needs, addiction or dual diagnosis histories, and blended family dynamics.
KAP may be supportive when a client is not only looking for relief, but also seeking a deeper reorganization of how they relate to themselves, their body, their history, and their relationships.
So, Is Ketamine-Assisted Therapy Evidence-Based?
Yes — with nuance.
Ketamine itself has a substantial evidence base for rapid antidepressant effects, especially in treatment-resistant depression. Esketamine has FDA approval for specific depression indications, while racemic ketamine for psychiatric conditions remains off-label.
Ketamine-assisted psychotherapy has a smaller but growing body of evidence. Current studies suggest KAP may support improvements in depression, anxiety, PTSD, substance use, and other concerns, especially when combined with preparation, therapeutic support, and integration. At the same time, the field still needs more rigorous randomized trials, longer follow-up periods, clearer protocols, and better understanding of which clients are most likely to benefit.
The most honest answer is this: ketamine-assisted therapy is evidence-informed, clinically promising, and increasingly researched. It should be practiced with humility, careful screening, medical collaboration, trauma-informed skill, and respect for both its potential and its limitations.
For some clients, ketamine may reduce symptoms. For others, when paired with therapy, it may also support emotional processing, attachment healing, identity work, nervous-system regulation, and long-term behavioral change.
That is where the promise of ketamine-assisted therapy lives — not in the medicine alone, but in the relationship between the medicine, the therapeutic container, and the client’s capacity to integrate new possibilities into everyday life.
Learn more about my approach to therapy & coaching for PMDD and trauma therapy.
